Moderna
@moderna_tx
Followers
149,741
Following
560
Media
1,446
Statuses
2,594
Our mission is to deliver the greatest possible impact to people through mRNA medicines.
Cambridge, MA
Joined December 2013
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Amethi
• 151768 Tweets
Knicks
• 141113 Tweets
राहुल गांधी
• 125929 Tweets
Sixers
• 71881 Tweets
Brunson
• 69048 Tweets
Pacers
• 62764 Tweets
憲法記念日
• 62541 Tweets
Embiid
• 57203 Tweets
Philly
• 55693 Tweets
#Raebareli
• 54220 Tweets
Dua Lipa
• 36098 Tweets
Maxey
• 31451 Tweets
Bruins
• 27486 Tweets
FREENBECKY IS OUR HOME
• 27304 Tweets
76ers
• 25525 Tweets
Rony
• 25409 Tweets
連休初日
• 23768 Tweets
#FattuPappu
• 22705 Tweets
Tobias Harris
• 21326 Tweets
Pachuca
• 21125 Tweets
स्मृति ईरानी
• 20137 Tweets
Josh Hart
• 20084 Tweets
ゴジラ-1.0
• 19699 Tweets
पूर्व मुख्यमंत्री
• 19271 Tweets
Smriti Irani
• 18964 Tweets
Hield
• 16949 Tweets
Hayırlı Cumalar
• 16903 Tweets
Pumas
• 15360 Tweets
チャレンジクルー
• 15174 Tweets
किशोरी लाल शर्मा
• 14981 Tweets
KerenTIMNASKU STYdanERICK
• 12445 Tweets
TetapSMANGAT GarudaMUDAKU
• 12067 Tweets
Wayanad
• 11775 Tweets
We just announced that the Moderna COVID-19 Vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the Republic of South Africa. Read more:
318
7K
21K
Today, we shared positive pre-clinical data demonstrating our ability to combine 6 mRNAs against 3 different respiratory viruses in 1 vaccine: COVID-19 booster + Flu booster + RSV booster.
#mRNA
834
6K
18K
We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study.
Read more:
241
2K
6K
We just announced the primary efficacy analysis in the Phase 3 COVE study for mRNA-1273, our COVID-19 vaccine candidate and that today, we plan to request an Emergency Use Authorization from the U.S. FDA & conditional approval from the EMA. Read more:
171
2K
5K
We just announced that the Philippines has secured 7 million additional doses of our COVID-19 vaccine through a new supply agreement & partnership with the private sector, bringing its confirmed order commitment to 20 million doses. Read more:
67
1K
5K
We just announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, our vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. Read more:
343
990
3K
158
1K
3K
We just announced our strategy to address the omicron (B.1.1.529) SARS-CoV-2 variant. Read more:
258
807
2K
We just announced a longer shelf life at refrigerated temperatures for mRNA-1273, our COVID-19 vaccine candidate. Read more:
66
503
2K
Update: Moderna’s data for the Emergency Use Authorization request for mRNA-1273 has been submitted to the U.S. FDA.
48
351
2K
We just announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government of Taiwan for 5 million doses and another with the government of Colombia for 10 million doses. Read more:
58
530
2K
We just announced positive interim Phase 1 data for our mRNA vaccine (mRNA-1273) against novel coronavirus. Read more:
79
602
1K
We just announced that the FDA has authorized the Moderna COVID-19 Vaccine in the U.S. for emergency use to prevent COVID-19 in individuals 18 and over. The Moderna COVID-19 Vaccine has not been approved or licensed by the FDA.
70
476
1K
We just announced a supply update for the Moderna COVID-19 Vaccine in the United States, reporting that 45.4 million doses have been supplied to the U.S. Government to date. Read more:
65
281
1K
None of this would be possible without our partnerships, and we are grateful to
@gatesfoundation
,
@scrippsresearch
,
@UTSA
,
@GWtweets
,
@fredhutch
, and
@EmoryUniversity
.
13
112
1K
We just confirmed that the
@US_FDA
VRBPAC recommended that the FDA grant an Emergency Use Authorization for our COVID-19 vaccine candidate, mRNA-1273. 20 VRBPAC members recommended for EUA, 0 members voted against, and 1 abstained. Read more:
41
322
1K
We just announced that the first participants have been dosed with our modified COVID-19 vaccines, designed to address the potential need for booster vaccine candidates, in an amendment to the ongoing Phase 2 clinical study. Read more:
33
333
1K
We just announced an expansion of our agreement with
@BARDA
for up to an additional $472 million to support our late stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. Read more:
53
358
921
We just announced that the first participant has been dosed in the NIH-led Phase 1 study of our
#mRNA
vaccine (mRNA-1273) against novel coronavirus
38
399
884
What if
#mRNA
could treat life-threatening
#cardiovascular
diseases such as
#HeartFailure
? We are collaborating with
@AstraZeneca
on an mRNA therapeutic (AZD8601) that encodes for VEGF-A to promote recovery of cardiac function through tissue regeneration.
18
460
839
We're announcing positive interim data from the Phase 2/3 KidCOVE study of our
#COVID19
vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age.
1
338
879
Moderna is developing an investigational mRNA vaccine against cytomegalovirus. Learn more about
#CMV
here:
#StopCMV
#CMVawareness
22
143
807
Breaking: Moderna announces a supply agreement with the U.S. government to secure an initial 100 million doses of mRNA-1273 for up to $1.525 billion with option granted to U.S. government to purchase up to an additional 400 million doses
67
263
748
We just announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the COVID-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021. Read more:
44
185
728
We just announced that the Phase 2/3 study of our COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint. In the study, no cases of COVID-19 were observed in participants who had received 2 doses of the vaccine:
26
217
701
We just announced the U.S. gov't has exercised the 1st option for an additional 100 million doses of our COVID-19 vaccine candidate, which will be delivered in Q2 2021. Read more:
41
157
667
The authorized 50 µg booster of mRNA-1273 increased neutralizing antibody levels against Omicron ~37-fold compared to pre-boost levels & a 100 µg dose of mRNA-1273 increased neutralizing antibody levels ~83-fold compared to pre-boost levels. Read more:
87
337
661
This morning, we announced a U.S. supply update for the Moderna COVID-19 Vaccine, reporting that 30.4 million doses have been supplied to the U.S. Government to date. We remain on track deliver 100 million doses to the USG by end of March 2021. Read more:
36
175
638
Update: The European Medicines Agency has received Moderna’s application for conditional marketing authorization of our COVID-19 vaccine
37
114
609
We just announced that we have completed enrollment of 30,000 participants for the Phase 3 COVE study of mRNA-1273, our vaccine candidate against COVID-19. Read more:
26
128
604
100 days after receiving Emergency Use Authorization from the U.S. FDA, we are proud to share that we’ve shipped the 100-millionth dose of our COVID-19 vaccine to the U.S. Government. Read more:
34
127
581
We just announced that we have shipped vials of mRNA-1273, the Company’s vaccine against the novel coronavirus, to the NIH to be used in the planned Phase 1 study in the U.S.
27
530
566
We just announced that Health Canada has authorized the Moderna COVID-19 Vaccine in Canada. Read more:
26
135
564
We just announced that the UK’s MHRA has approved our mRNA vaccine against COVID-19 for use. The UK government also secured an additional 10 million doses of the COVID-19 Vaccine Moderna. Read more:
42
155
550
Respiratory viruses are a leading cause of many hospitalizations and deaths. We believe Moderna could be first to market with a COVID + Flu + RSV booster vaccine. A single vaccine to cover multiple viruses.
#IDWeek2021
37
118
564
We are pleased to announce that today we completed our submission to the
@US_FDA
, which we began on Wednesday, for the evaluation of a booster dose of the Moderna COVID-19 vaccine.
45
127
552
And third, we are rapidly advancing a Omicron-specific booster candidate (mRNA-1273.529).
Second, we are already studying two multi-valent booster candidates in the clinic that were designed to anticipate mutations such as those that have emerged in the Omicron variant.
19
98
323
85
163
537
We also announced that we have increased our 2021 base plan to 700 million doses and we working to supply up to 1 billion doses in 2021. Read more:
17
116
515
Ongoing development data related to the current formulation of our COVID-19 vaccine could support a 3-month refrigerated (2-8°C) shelf life for the vaccine in alternative formats to facilitate easier distribution to doctor’s offices & other smaller settings if authorized.
12
127
510
We announced a new supply agreement with Australia for 25 million doses of our COVID-19 vaccine, including 10 million doses of our vaccine against the ancestral strain for in 2021 & 15 million doses of our variant booster candidate for delivery in 2022:
43
146
507
We just confirmed that the Company is engaged in discussions with the government of South Korea to potentially provide 40 million or more doses of the Moderna COVID-19 Vaccine. Read more:
20
309
495
We just announced that the first adolescent participants have been dosed in the Phase 2/3 study of mRNA-1273, our vaccine candidate against COVID-19, in adolescents ages 12 to less than 18. Read more:
25
129
486
We are pleased to share that Health Canada has authorized our
#mRNA
COVID-19 vaccine in Canada to include immunization to prevent COVID-19 caused by the SARS-CoV-2 virus in adolescents 12 years of age and older under the Interim Order.
48
116
488
This evening, we announced that the U.S. government has purchased an additional 100 million doses of Moderna’s COVID-19 Vaccine, bringing its confirmed order commitment to 300 million doses.
20
112
473
Now available as a preprint on bioRxiv: mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. Read more here:
6
181
479
We just announced that the European Commission has approved an agreement to secure 80 million doses of mRNA-1273, with the option to increase their purchase to a total of up to 160 million doses. Read more:
#mRNA
35
99
473
We just announced that we have completed case accrual for the first planned interim analysis of mRNA-1273, our mRNA vaccine against COVID-19. Read more:
23
108
472
We just announced that the European Commission has exercised its option to purchase an additional 80 million doses of mRNA-1273, our COVID-19 vaccine candidate, bringing its confirmed order commitment to 160 million doses. Read more:
27
132
471
We also announced that out of an abundance of caution, we are launching a clinical program to boost immunity to emerging variants. Learn more:
20
177
474
We just announced that Israel’s Ministry of Health (MOH) has given authorization to import the COVID-19 Vaccine Moderna in Israel. Read more here:
23
123
460
Emerging real-world evidence confirms Moderna efficacy against COVID-19 wild-type virus and variants of concern (VOCs), including Alpha, Beta/Gamma and Delta VOC, even after partial vaccination.
25
246
472
Earlier today, we announced a supply agreement to provide 13 million doses of COVID-19 Vaccine Moderna to the Philippines. Read more:
19
111
465
We are pleased to share a preprint of the preclinical manuscript for our
#vaccine
against
#SARS
-CoV-2 to potentially prevent
#COVID19
disease. We thank the NIAID team for their collaboration with our infectious disease research team.
@NIAIDNews
16
196
458
We just announced that we have received confirmation of eligibility for submission of a Marketing Authorization Application to the European Medicines Agency for mRNA-1273
13
134
456
This morning, we announced that the Canadian government has increased its confirmed order commitment by 20 million doses of mRNA-1273, our vaccine candidate against COVID-19, bringing its confirmed order commitment to 40 million doses. Read more:
46
107
448
We are pleased to share that as of today, Friday, August 21st, 13,194 participants have been enrolled in the COVE Phase 3 study of mRNA-1273. Find out more about the trial here: . Check back next Friday evening for an updated enrollment number.
29
129
448
We just announced that we have submitted an IND application to the U.S. FDA for a Phase 2 study of our mRNA Vaccine (mRNA-1273) against novel coronavirus. Read more:
30
132
435
New preclinical data shows variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern. Read more:
12
110
436
We just announced that the first participants in each age cohort have been dosed in the Phase 2 study of our mRNA vaccine (mRNA-1273) against novel coronavirus. Read more:
#mRNA
28
156
428
While the pandemic continues, Moderna will not enforce our COVID-19 related patents against those making vaccines intended to combat the pandemic. Read our statement here:
28
130
425
We are grateful for the opportunity to present the clinical data package for our COVID-19 booster vaccine to the FDA’s advisory committee today. We thank the committee for their review & for their unanimous vote in support of EUA of the 50 µg booster dose.
26
100
421
We just provided an update on mRNA-1273, our COVID-19 vaccine candidate, including interim durability data from the NIH-led Phase 1 study of mRNA-1273 and a production update. Read more:
32
91
390
To provide additional transparency in context of pandemic, the protocol for the Phase 3 COVE study of mRNA-1273 being conducted in collaboration with the NIH and BARDA is now available:
#mRNA
8
179
400
Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at
22
100
386
Moderna confirms advanced discussions with the European Commission to purchase an initial 80 million doses of mRNA-1273 with the option to purchase up to an additional 80 million doses.
20
62
388
Earlier today we announced that we shipped our variant-specific vaccine candidate, mRNA-1273.351, to the
@NIH
for a Phase 1 clinical trial that will be led and funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Read more:
10
136
387
Today, we are sharing an important update about our protocol for the Phase 3 COVE Study of mRNA-1273, our vaccine candidate against COVID-19.
27
108
375
We are pleased to share that as of today, Friday, September 4th, 21,411 participants have been enrolled in the COVE Phase 3 study of mRNA-1273. Find out more about the trial here: . Check back next Friday evening for an updated enrollment number.
31
102
376
We just announced an agreement in principle with the Australian Government to build a state-of-the-art
#mRNA
vaccine manufacturing facility in Victoria, Australia including access to our mRNA development engine. Read more:
26
61
380
We just announced a supply agreement with the United Kingdom government to supply mRNA-1273, our mRNA vaccine against COVID-19 if approved for use. Read more:
26
53
364
We announced today clinical trial data for our updated COVID-19 vaccine candidate in humans against BA.2.86 (Pirola), a variant under monitoring. Read more ⬇
0
147
381
We just announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, our next generation COVID-19 vaccine candidate. Read more:
9
72
368
We just announced that we have concluded advanced exploratory talks with the European Commission to supply 80 million doses of mRNA-1273. Read more here:
18
108
368
We just announced an amendment to the current supply agreement with the United Kingdom government for an additional 2 million doses of mRNA-1273, our
#mRNA
vaccine candidate against COVID-19. Read more:
31
74
362
This evening, we are highlighting the publication of antibody persistence data out to 6 months following the second dose of the Moderna COVID-19 Vaccine in
@NEJM
. Read more:
27
78
368
Today, we announced that we will build a state-of-the-art
#mRNA
facility in Africa to manufacture up to 500 million doses per year. Since our founding in 2010, our mission has been to make a transformative impact on human lives through our medicines:
31
72
373
We just announced that the the European Commission purchased an additional 150 million doses of the COVID-19 Vaccine Moderna, to be delivered in Q3 & Q4 2021. This brings its confirmed order commitment to 310 million doses. Read more:
10
81
358
We just announced a supply agreement with the U.S. government for an initial 100 million doses of mRNA-1273, our vaccine candidate against COVID-19. Read more here:
41
124
345
However, a
#booster
dose of mRNA-1273 at the 50 µg dose level significantly increased neutralizing
#antibody
titers against
#Omicron
. These and additional data have been submitted to a preprint server.
First look at the assessment of our COVID-19 vaccine & 50µg booster against
#Omicron
. After the 2-dose primary series of our vaccine, while individuals had detectable neutralizing titers against Omicron, neutralizing titers were significantly lower compared to the wild-type virus
14
48
158
34
151
353